Skip to content

    JB Chemicals & Pharmaceuticals Limited

    JBCHEPHARMStrong
    Healthcare·15 May 2025
    Management Summary

    J B Chemicals delivered a strong Q4 FY25, characterized by consistent outperformance in the domestic chronic segment and a recovery in the CDMO business. The company is successfully transitioning its international mix toward higher-margin private markets and CDMO projects. Management's decision to raise EBITDA margin guidance to 27-29% reflects high confidence in operating leverage and the upcoming margin-accretive transition of the ophthalmology portfolio.

    Highlights

    8

    • Revenue for Q4 FY25 grew 10% YoY to ₹949 crore; full-year FY25 revenue reached ₹3,918 crore (up 12%)

    • Operating EBITDA expanded 15% YoY to ₹240 crore, with margins improving 90 bps to 25.3%

    • Net Profit for the quarter increased 15% to ₹146 crore; full-year PAT rose 19% to ₹660 crore

    • Domestic business outpaced the Indian Pharma Market (IPM) with 13% growth vs 7% industry growth

    • CDMO segment grew 18% in Q4 to ₹129 crore, with a target run rate of ₹150 crore per quarter

    • Management raised operating EBITDA margin guidance for the third consecutive year to a range of 27-29%

    • Board recommended a final dividend of ₹7 per share, taking the total FY25 dividend to ₹15.50 per share

    • Net cash position strengthened significantly to ₹689 crore as of March 31, 2025

    What Changed1

    vs Q1 FY26

    Tone shiftGood → Strong

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue₹949 Cr+10%YoY
    2. 02Operating EBITDA₹240 Cr+15%YoY
    3. 03EBITDA Margin25.3%
    4. 04Net Profit₹146 Cr+15%YoY
    5. 05Gross Margin66.1%

    Segment breakdown

    • Domestic Business₹519 Cr48.1%
    • International Operations₹430 Cr39.9%
    • CDMO₹129 Cr12.0%
    Donut· Share of Revenue

    Guidance & targets

    5
    CategoryTargetPriority
    Margin
    Operating EBITDA Margin
    27-29%
    		High
    Revenue
    CDMO Quarterly Run Rate
    ₹150 crore
    		High
    Revenue
    Ophthalmology Annualized Run Rate
    ₹230 crore
    		Medium
    Capex
    Annual Capex
    ₹100 crore
    		High
    Other
    ESOP Expenses
    ₹41-46 crore
    		Medium

    Risks & concerns

    5
    RiskSeverity

    Regulatory monitoring of Rantac

    Government has instructed manufacturers to closely monitor quality; management remains confident in its safety profile. — Both acknowledged

    medium

    Decline in third-party API sales

    Third-party sales of diclofenac are in a mature/declining phase; company is pivoting to captive consumption for US ANDAs. — Analyst downplayed

    low

    Red Sea logistics issues

    Management noted trends are consistent with no significant deviation in international freight costs currently. — Management acknowledged

    low

    Areas of Evasion(2)

    • Promoter stake sale timeline
    • Specific profitability of individual business units

    Q&A highlights

    3

    “So there is no ban on the product, Rantac continues to be made available to the patients given its very strong clinical efficacy and safety profile.”

    Rantac is a major brand; management clarified that while quality monitoring is increased, there is no ban, mitigating a significant regulatory concern.

    asked by Tausif, BNP Paribas

    2 min read5 chapters

    Detailed Narrative

    01

    Domestic Chronic Portfolio Drives Outperformance

    J B Chemicals' domestic business grew 13% in Q4 FY25, significantly outpacing the IPM's 7% growth. The chronic portfolio was the primary driver, growing at 16% YoY, led by flagship brands like Cilacar (up 19%) and Cilacar T (up 37%). The company now covers 3.5 lakh doctors and has improved field force productivity to ₹8 lakh PCPM from ₹4.6 lakh in FY21.

    02

    CDMO Segment Poised for Step-Jump in Revenue

    The CDMO business reported 18% growth in Q4 with revenue of ₹129 crore. Management expects the quarterly run rate to increase from the current ₹110 crore to ₹150 crore by FY26. This growth is underpinned by new projects in lozenges, throat sprays, and iodine-based formulations for the US and European markets.

    03

    Ophthalmology Portfolio: A Margin Catalyst for FY27

    The acquired ophthalmology portfolio is currently operating at a quarterly run rate of ₹48 crore with gross margins around 20%. A critical value-unlocking event is scheduled for December 2026, when the perpetual license triggers. This will transition the portfolio to owned trademarks, shifting gross margins toward the company average of ~66% and significantly boosting overall EBITDA.

    04

    International Business Mix Optimization

    The company is successfully restructuring its international operations, particularly in South Africa, where it shifted from a tender-heavy model to a 65-70% private market mix. This move, while involving a ₹120 crore revenue cut in low-margin tenders, has substantially improved segment profitability. Russia remains a strong contributor with double-digit growth in branded generics.

    05

    Robust Cash Generation and Dividend Payout

    JB Pharma reported one of the highest operating cash flow to EBITDA metrics in the industry at 83%, with FY25 operating cash flows reaching ₹903 crore. This strong cash generation supported a total dividend payout of ₹15.50 for the year and left the company with a net cash surplus of ₹689 crore, providing significant headroom for future inorganic acquisitions.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.